WO2010039778A3 - Mammalian genes involved in infection - Google Patents

Mammalian genes involved in infection Download PDF

Info

Publication number
WO2010039778A3
WO2010039778A3 PCT/US2009/058947 US2009058947W WO2010039778A3 WO 2010039778 A3 WO2010039778 A3 WO 2010039778A3 US 2009058947 W US2009058947 W US 2009058947W WO 2010039778 A3 WO2010039778 A3 WO 2010039778A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
genes involved
mammalian genes
involved
sequences
Prior art date
Application number
PCT/US2009/058947
Other languages
French (fr)
Other versions
WO2010039778A2 (en
Inventor
Donald Rubin
Thomas Hodge
James Murray
Natalie Mcdonald
Original Assignee
Zirus, Inc.
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zirus, Inc., Vanderbilt University filed Critical Zirus, Inc.
Priority to EP09818408A priority Critical patent/EP2362909A4/en
Publication of WO2010039778A2 publication Critical patent/WO2010039778A2/en
Publication of WO2010039778A3 publication Critical patent/WO2010039778A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • C12Y601/01005—Isoleucine-tRNA ligase (6.1.1.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to nucleic acid sequences and cellular proteins encoded by these sequences that are involved in infection or are otherwise associated with the life cycle of one or more pathogens.
PCT/US2009/058947 2008-09-30 2009-09-30 Mammalian genes involved in infection WO2010039778A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09818408A EP2362909A4 (en) 2008-09-30 2009-09-30 Mammalian genes involved in infection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19477408P 2008-09-30 2008-09-30
US61/194,774 2008-09-30
US19577008P 2008-10-09 2008-10-09
US61/195,770 2008-10-09

Publications (2)

Publication Number Publication Date
WO2010039778A2 WO2010039778A2 (en) 2010-04-08
WO2010039778A3 true WO2010039778A3 (en) 2010-09-16

Family

ID=42074170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/058947 WO2010039778A2 (en) 2008-09-30 2009-09-30 Mammalian genes involved in infection

Country Status (2)

Country Link
EP (1) EP2362909A4 (en)
WO (1) WO2010039778A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6073795B2 (en) * 2010-10-27 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1)
CA2862485C (en) * 2012-01-24 2021-05-11 Inter-K Pty Limited Peptide agents for cancer therapy
FR2987627B1 (en) * 2012-03-05 2016-03-18 Splicos USE OF RBM39 AS A BIOMARKER
JP6246199B2 (en) * 2012-07-02 2017-12-13 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Paramyxovirus and usage
EP3572513A1 (en) * 2013-12-09 2019-11-27 Baylor College of Medicine Hippo and dystrophin complex signaling in cardiomyocyte renewal
WO2019119036A1 (en) * 2017-12-19 2019-06-27 Benitec Biopharma Limited Cd70 deficient cells, and methods and reagents for producing same
CN108707607A (en) * 2018-06-08 2018-10-26 邵玉芹 A kind of aptamers and kit of energy specific detection EV71 viruses
CN113274510B (en) * 2021-04-29 2022-05-13 山东农业大学 Composition for inhibiting J subgroup avian leukosis virus replication and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018505A1 (en) * 2001-06-29 2004-01-29 Lee Ernestine A. Aminoacyl trna synthetases
US20060079474A1 (en) * 2004-10-07 2006-04-13 Paul Glidden Analogs of tRNA synthetase fragments and uses thereof
WO2007084488A2 (en) * 2006-01-13 2007-07-26 Vanderbilt University Adam10 and its uses related to infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018505A1 (en) * 2001-06-29 2004-01-29 Lee Ernestine A. Aminoacyl trna synthetases
US20060079474A1 (en) * 2004-10-07 2006-04-13 Paul Glidden Analogs of tRNA synthetase fragments and uses thereof
WO2007084488A2 (en) * 2006-01-13 2007-07-26 Vanderbilt University Adam10 and its uses related to infection

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDREW J. POPE ET AL.: "Characterization of Isoleucyl-tRNA Synthetase from Staphylococcus aureus", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 48, 27 November 1998 (1998-11-27), pages 31691 - 31701, XP008147617 *
CURTIS F. CRASTO ET AL.: "Synthesis and Activity of Analogues of the Isoleucyl tRNA Synthetase Inhibitor SB-203207", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 11, 2003, pages 2687 - 2694, XP008147616 *
DEZHONG YIN ET AL.: "Identification of antimicrobial targets using a comprehensive genomic approach", PHARMACOGENOMICS, vol. 5, no. 1, 2004, pages 101 - 113, XP009055699 *
PAUL SCHIMMEL ET AL.: "Aminoacyl tRNA synthetases as targets for new anti-infectives", FASEB J, vol. 12, 1998, pages 1599 - 1609, XP002191843 *
See also references of EP2362909A4 *

Also Published As

Publication number Publication date
EP2362909A4 (en) 2012-10-10
WO2010039778A2 (en) 2010-04-08
EP2362909A2 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
WO2011008956A3 (en) Mammalian genes involved in infection
WO2010134939A3 (en) Mammalian genes involved in infection
WO2010039778A3 (en) Mammalian genes involved in infection
WO2006047673A3 (en) Mammalian genes involved in infection
WO2011146527A3 (en) Mammalian genes involved in infection
WO2010110914A3 (en) Mammalian genes involved in infection
WO2011063308A3 (en) Beta-glucosidase variants with improved properties
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
EP2274442A4 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
GB2470672B (en) Methods of RNA amplification in the presence of DNA
PE20190843A1 (en) RNA ADDRESSING TO GENERIC DNA
WO2009120374A3 (en) Methods and compositions for nucleic acid sample preparation
WO2010127304A3 (en) Sequencing methods
WO2009126623A3 (en) Expression of heterologous sequences
MX2013012844A (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same.
PT2304054T (en) Isothermal nucleic acid amplification
WO2010120508A3 (en) Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders
EP2377928A3 (en) Novel T7 RNA polymerase variants with enhanced thermostability
HK1142928A1 (en) Nucleic acid amplification in the presence of modified randomers
WO2012061502A3 (en) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
WO2007084488A3 (en) Adam10 and its uses related to infection
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
WO2012045067A3 (en) Mammalian genes involved in infection
WO2010144908A3 (en) Mammalian genes involved in tularemia and other infections
IN2012DN00172A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09818408

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011530157

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2009818408

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP